Admin

Plunging 14% at the open, Nike warns of declining revenue in 2026, with the Middle East situation and high inflation dragging on the recovery process.

Plunging 14% at the open, Nike warns of declining revenue in 2026, with the Middle East situation and high inflation dragging on the recovery process.

Nike released a forecast far more pessimistic than market expectations, raising investor concerns about whether the sports brand’s multi-year transformation plan can progress as scheduled. The company warned that **revenue may decline in fiscal 2026, and the current quarter is also under pressure**. Due to disruptions in Europe and
Admin
```
AI strategy lagging behind, unclear successor, stock price down nearly 7% this year... Apple faces five major soul-searching questions on its 50th anniversary.
```

``` AI strategy lagging behind, unclear successor, stock price down nearly 7% this year... Apple faces five major soul-searching questions on its 50th anniversary. ```

``` As it celebrates its 50th anniversary, Apple finds itself at a crossroads full of uncertainty. The tech giant, which once reshaped the consumer electronics industry with the iPod and iPhone, now faces multiple challenges including lagging behind in AI deployment, lack of hardware innovation, pressure in the Chinese market, and
Admin
From weight loss drugs to tackling sleep disorders! Eli Lilly plans to acquire Centessa for up to $7.8 billion, entering the treatment field for narcolepsy and wakefulness disorders.

From weight loss drugs to tackling sleep disorders! Eli Lilly plans to acquire Centessa for up to $7.8 billion, entering the treatment field for narcolepsy and wakefulness disorders.

``` Eli Lilly is leveraging its strong capital accumulated in the obesity field to bet on the next high-potential health sector. The American pharmaceutical giant announced that it will acquire the biotechnology company Centessa Pharmaceuticals for up to $7.8 billion, marking the second largest acquisition in Lilly’s history. Centessa
Admin